CAR-Treg Deal Benchmarks in Immunology & Autoimmune

Median Upfront

$767M

Range: $398M - $1.1B

Total Deal Value

$4.2B

Range: $2.6B - $5.8B

Royalty Rate

15.5% - 25.8%

Tiered up to 29.8%

Dev Milestones

$688M

Range: $442M - $935M

Model Your Deal

Market Analysis

CAR-Treg therapies in immunology & autoimmune have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 car-treg asset in immunology & autoimmune is $767M, with total deal values reaching $4.2B. Development milestones average $688M, while regulatory milestones contribute $1.2B.

The immunology & autoimmune car-treg landscape is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape. The recommended deal structure allocates approximately 18% to upfront payments and 82% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for car-treg immunology & autoimmune deals range from 15.5% to 25.8% at the base tier, with tiered escalation reaching 19.5%-29.8% on blockbuster sales. Commercial milestones averaging $1.5B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a car-treg immunology & autoimmune licensing deal?

Based on our analysis, Phase 2 car-treg licensing deals in immunology & autoimmune average $767M in upfront payments, with a range of $398M to $1.1B depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for car-treg immunology & autoimmune transactions?

The median total deal value for Phase 2 car-treg assets in immunology & autoimmune is $4.2B, ranging from $2.6B to $5.8B. This includes development milestones ($688M), regulatory milestones ($1.2B), and commercial milestones ($1.5B).

What royalty rates are standard for car-treg deals in immunology & autoimmune?

Base royalty rates for car-treg immunology & autoimmune transactions range from 15.5% to 25.8%, with tiered escalations reaching 19.5%-29.8% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in car-treg immunology & autoimmune deals?

CAR-Treg immunology & autoimmune deals allocate approximately 82% of total deal value to milestones. Development milestones ($688M) make up the largest share, followed by commercial milestones ($1.5B) and regulatory milestones ($1.2B).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Immunology & Autoimmune

View

Monoclonal Antibody in Immunology & Autoimmune

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included